Showing results (21-30 of 191) with videos related to
Sort By:
Pageof 20
Journal of Pharmaceutical and Biomedical Analysis|July 26, 2016
LC-MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasmaJulianne L Holleran, Julie L Eiseman, Robert A Parise, et al.Pharmacotherapy|June 29, 2006
Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndromeJan H Beumer, James J Natale, Theodore F Lagattuta, et al.Pharmacotherapy|August 25, 2009
Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemiaCarolina Pavlovsky, Merrill J Egorin, Dhvani D Shah, et al.Journal of Pharmaceutical and Biomedical Analysis|December 2, 2016
LC-MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasmaBrian F Kiesel, Robert A Parise, Alvin Wong, et al.BMC Cancer|October 7, 2015
Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinomaJan H Beumer, Katherine Y Fu, Bean N Anyang, et al.Cancer Chemotherapy and Pharmacology|September 14, 2016
Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumorsMartin J Edelman, Rena Lapidus, Josephine Feliciano, et al.Cancer Letters|February 2, 2024
Impact of the 2021 CKD-EPI equation on anticancer pharmacotherapy in black and non-black cancer patientsMorgan A Butrovich, Jiyue Qin, Xiaonan Xue, et al.Steroids|January 31, 2012
A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D(3) is revealed using a novel LC-MS/MS assayJan H Beumer, Robert A Parise, Beatriz Kanterewicz, et al.Cancer Chemotherapy and Pharmacology|December 22, 2015
A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysisJennifer R Eads, Jan H Beumer, Lavinia Negrea, et al.Cancer Chemotherapy and Pharmacology|September 3, 2015
Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinibJohn F Deeken, Jan H Beumer, Nicole M Anders, et al.Pageof 20